Endoglin concentration in peritoneal fluid of patients with endometriosis

  • Nusratuddin Abdullah
Keywords: Endoglin, endometriosis, peritoneum
Abstract viewed: 1277 times
PDF downloaded: 469 times


Background: Endoglin is a specific angiogenic factor suspected to involve in the pathogenesis of endometriosis. The aim of this study was to evaluate the significance of endoglin concentration in the peritoneal fluid of patients with endometriosis.

Methods: This pilot study was performed between March 2011 and July 2012 at Dr. Wahidin Sudirohusodo Hospital and another private hospital in Makassar, Indonesia. This was an observational, cross-sectional study. All patients undergoing laparoscopy for infertility and other cases with suitable inclusion criteria were asked to answer a questionnaire and had a 5 cc peritoneal fluid sample taken for measurement of peritoneal endoglin concentration using ELISA. Endometriosis stage was classified using ASRM criteria and divided into two groups, mild and severe. All data were analyed using Excel and Spearman correlation analysis.

Results: In the endometriosis group peritoneal endoglin concentration ranged between 14.43- 15.65 ng/mL (median 15.04 ng/mL) which is higher than control group 7.42-10.26 ng/mL (median 8.84 ng/mL). A peritoneal endoglin concentration equal to or higher than 11 ng/mL could be used to predict endometriosis.

Conclusion: Endoglin concentrations increased proportionally with the severity of endometriosis, and many be used as predictive factor of endometriosis cases. (Med J Indones. 2013;22:88-91)


  1. Gupta S, Agarwal A, Sekhon L, Krajcir N, Cocuzza M, Falcone T. Serum and peritoneal abnormalities in endometriosis: potential use as diagnostic markers. Minerva Ginecol. 2006;58(6):527-51.

  2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511-9.

  3. Groothuis PG, Nap AW, Winterhager E, Grummer R. Vascular development in endometriosis. Angiogenesis 2005;8(2):147-56.

  4. Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004;89(3):1089-95.

  5. Taylor RN, Yu J, Torres PB, et al. Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci. 2009;16(2):140-6.

  6. Hayrabedyan S, Kyurkchiev S, Kehayov I. Endoglin (cd105) and S100A13 as markers of active angiogenesis in endometriosis. Reprod Biol. 2005;5(1):51-67.

  7. Kim SH, Choi YM, Chae HD, Kim KR, Kim CH, Kang BM. Increased expression of endoglin in the eutopic endometrium of women with endometriosis. Fertil Steril 2001;76(5):918-22.

  8. Fujishita A, Hasuo A, Khan KN, Masuzaki H, Nakashima H, Ishimaru T. Immunohistochemical study of angiogenic factors in endometrium and endometriosis. Gynecol Obstet Invest. 1999;48 Suppl 1:36-44.

  9. Pelch KE, Schroder AL, Kimball PA, Sharpe-Timms KL, Davis JW, Nagel SC. Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women. Fertil Steril 201015;93(5):1615-27 e18.

  10. Banerjee S, Dhara SK, Bacanamwo M. Endoglin is a novel endothelial cell specification gene. Stem Cell Res. 2012;8(1):85-96.

  11. Perez-Gomez E, Del Castillo G, Juan Francisco S, Lopez Novoa JM, Bernabeu C, Quintanilla M. The role of the TGF-beta coreceptor endoglin in cancer. ScientificWorldJournal 2010;10:2367-84.

  12. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14(7):1931-7.

  13. Healy DL, Rogers PA, Hii L, Wingfield M. Angiogenesis: a new theory for endometriosis. Hum Reprod Update. 1998;4(5):736-40.

  14. Abdullah N. Analysis of vascular endothelial growth factor (VEGF) gene polymorphisms in endomometriosis. Makassar: Universitas Hasanuddin; 2008. Indonesian.

  15. Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY. Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod. 2005;20(10):2904-8.

  16. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci. 2002;955:11-22.

  17. McLeod BS, Retzloff MG. Epidemiology of endometriosis: an assessment of risk factors. Clin Obstet Gynecol. 2010;53(2):389-96.

  18. Chu KK, Chen FP, Chang SD. Prevalence of endometriosis among women undergoing laparoscopic procedures. Diagnostic and Therapeutic Endoscopy 1995;2(1):35-7.

  19. Bedaiwy MA, Falcone T. Laboratory testing for endometriosis. Clin Chim Acta. 2004;340(1-2):41-56.

  20. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci. 2002;955:89-100.

  21. Kadija S, Stefanovic A, Jeremic K, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22(2):238-44.

  22. Maio M, Altomonte M, Fonsatti E. Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res. 2006;69(4):781-3.

How to Cite
Abdullah N. Endoglin concentration in peritoneal fluid of patients with endometriosis. Med J Indones [Internet]. 2013Jun.1 [cited 2023Mar.22];22(2):88-1. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/535
Clinical Research